SG11201700114WA - Disintegrin variants and pharmaceutical uses thereof - Google Patents
Disintegrin variants and pharmaceutical uses thereofInfo
- Publication number
- SG11201700114WA SG11201700114WA SG11201700114WA SG11201700114WA SG11201700114WA SG 11201700114W A SG11201700114W A SG 11201700114WA SG 11201700114W A SG11201700114W A SG 11201700114WA SG 11201700114W A SG11201700114W A SG 11201700114WA SG 11201700114W A SG11201700114W A SG 11201700114WA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical uses
- disintegrin variants
- disintegrin
- variants
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462040503P | 2014-08-22 | 2014-08-22 | |
PCT/US2015/046322 WO2016029131A1 (en) | 2014-08-22 | 2015-08-21 | Disintegrin variants and pharmaceutical uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201700114WA true SG11201700114WA (en) | 2017-02-27 |
Family
ID=55351297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201700114WA SG11201700114WA (en) | 2014-08-22 | 2015-08-21 | Disintegrin variants and pharmaceutical uses thereof |
Country Status (13)
Country | Link |
---|---|
US (2) | US10508137B2 (en) |
EP (1) | EP3182988A4 (en) |
JP (1) | JP6886917B2 (en) |
KR (1) | KR102102789B1 (en) |
CN (1) | CN106714818B (en) |
AU (1) | AU2015305299B2 (en) |
BR (1) | BR112017003334A8 (en) |
CA (1) | CA2958906C (en) |
MX (1) | MX2017002323A (en) |
RU (1) | RU2685869C1 (en) |
SG (1) | SG11201700114WA (en) |
TW (2) | TWI579299B (en) |
WO (1) | WO2016029131A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3182988A4 (en) * | 2014-08-22 | 2018-05-23 | National Cheng Kung University | Disintegrin variants and pharmaceutical uses thereof |
AU2016286432B2 (en) | 2015-06-28 | 2019-02-14 | Allgenesis Biotherapeutics Inc. | Fusion proteins for inhibiting angiogenesis |
IL247369B (en) * | 2016-08-18 | 2018-08-30 | B G Negev Tech And Applications Ltd | Modified m-csf polypeptides and use thereof |
WO2018167295A1 (en) * | 2017-03-17 | 2018-09-20 | Technische Universität München | LIGANDS FOR INTEGRIN αvβ8, SYNTHESIS AND USES THEREOF |
US11202854B2 (en) * | 2017-08-09 | 2021-12-21 | National Taiwan University | Disintegrin variants and uses thereof |
US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5380646A (en) * | 1992-10-19 | 1995-01-10 | Temple University Of The Commonwealth System Of Higher Education | Thrombus detection using radiolabelled disintegrins |
US7220724B2 (en) * | 1993-10-22 | 2007-05-22 | University Of Southern California | Contortrostatin CN and methods for its use in preventing metastasis and other conditions |
US7452551B1 (en) * | 2000-10-30 | 2008-11-18 | Imarx Therapeutics, Inc. | Targeted compositions for diagnostic and therapeutic use |
EP1274720A4 (en) * | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | Albumin fusion proteins |
JP2006521361A (en) * | 2003-03-24 | 2006-09-21 | セコイア、ファーマシューティカルズ、インコーポレイテッド | Long-acting bioactive conjugate |
US8183201B2 (en) * | 2006-12-26 | 2012-05-22 | National Cheng Kung University | Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin |
US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
EP2456454A4 (en) * | 2009-07-20 | 2013-03-20 | Univ Nat Cheng Kung | Polypeptides selective for av 3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof |
WO2011079175A1 (en) * | 2009-12-23 | 2011-06-30 | National Cheng Kung University | Compositions and methods for the treatment of angiogenesis-related eye diseases |
EP2910565A3 (en) * | 2010-02-11 | 2015-11-04 | University of Southern California | Modified ADAM disintegrin domain polypeptides and uses |
US8946159B2 (en) * | 2011-12-22 | 2015-02-03 | California Northstate College Of Pharmacy, Llc | Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment |
US20160317610A1 (en) * | 2013-09-25 | 2016-11-03 | University Of Southern California | Compositions and methods for treating ovarian cancer including preventing the recurrence thereof |
EP3182988A4 (en) * | 2014-08-22 | 2018-05-23 | National Cheng Kung University | Disintegrin variants and pharmaceutical uses thereof |
AU2016286432B2 (en) * | 2015-06-28 | 2019-02-14 | Allgenesis Biotherapeutics Inc. | Fusion proteins for inhibiting angiogenesis |
-
2015
- 2015-08-21 EP EP15834216.2A patent/EP3182988A4/en active Pending
- 2015-08-21 RU RU2017105771A patent/RU2685869C1/en active
- 2015-08-21 TW TW105137246A patent/TWI579299B/en active
- 2015-08-21 KR KR1020177007653A patent/KR102102789B1/en active IP Right Grant
- 2015-08-21 WO PCT/US2015/046322 patent/WO2016029131A1/en active Application Filing
- 2015-08-21 JP JP2017529973A patent/JP6886917B2/en active Active
- 2015-08-21 BR BR112017003334A patent/BR112017003334A8/en active Search and Examination
- 2015-08-21 CN CN201580038532.7A patent/CN106714818B/en active Active
- 2015-08-21 AU AU2015305299A patent/AU2015305299B2/en active Active
- 2015-08-21 CA CA2958906A patent/CA2958906C/en active Active
- 2015-08-21 SG SG11201700114WA patent/SG11201700114WA/en unknown
- 2015-08-21 US US15/505,357 patent/US10508137B2/en active Active
- 2015-08-21 TW TW104127347A patent/TWI563001B/en active
- 2015-08-21 MX MX2017002323A patent/MX2017002323A/en unknown
-
2019
- 2019-08-30 US US16/556,952 patent/US10870684B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10870684B2 (en) | 2020-12-22 |
US20170267731A1 (en) | 2017-09-21 |
TWI579299B (en) | 2017-04-21 |
AU2015305299A1 (en) | 2017-02-09 |
AU2015305299B2 (en) | 2018-11-01 |
RU2017105771A3 (en) | 2018-09-24 |
EP3182988A1 (en) | 2017-06-28 |
BR112017003334A8 (en) | 2018-02-06 |
US10508137B2 (en) | 2019-12-17 |
KR102102789B1 (en) | 2020-04-24 |
TW201609793A (en) | 2016-03-16 |
WO2016029131A1 (en) | 2016-02-25 |
TW201708250A (en) | 2017-03-01 |
KR20170042366A (en) | 2017-04-18 |
EP3182988A4 (en) | 2018-05-23 |
BR112017003334A2 (en) | 2017-11-28 |
TWI563001B (en) | 2016-12-21 |
MX2017002323A (en) | 2017-08-02 |
CN106714818A (en) | 2017-05-24 |
US20200010516A1 (en) | 2020-01-09 |
JP6886917B2 (en) | 2021-06-16 |
CN106714818B (en) | 2020-04-21 |
CA2958906A1 (en) | 2016-02-25 |
RU2017105771A (en) | 2018-09-24 |
RU2685869C1 (en) | 2019-04-23 |
CA2958906C (en) | 2021-05-04 |
JP2017525394A (en) | 2017-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244000B (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
IL252216A0 (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
HK1231471A1 (en) | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof 6-- 6--2- | |
HUE044571T2 (en) | Modified cyclopentapeptides and uses thereof | |
IL252967A0 (en) | Pharmaceutical composition comprising plasminogen and uses thereof | |
HK1252026A1 (en) | Pharmaceutical combination and uses thereof | |
ZA201703976B (en) | Dihydropyrimidine-2-one compounds and medicinal uses thereof | |
TWI563001B (en) | Disintegrin variants and pharmaceutical uses thereof | |
ZA201703398B (en) | Pharmaceutical composition and methods | |
ZA201701492B (en) | Pyrazolothiazole compound and medicine | |
LT3215143T (en) | Combination comprising spirulina and palmitoylethanolamide | |
IL250160A0 (en) | Pharmaceutical agent | |
PL3094338T3 (en) | Assay and medicament | |
PL3229772T3 (en) | 6-aryl-9-glycosylpurines and use thereof | |
GB201419354D0 (en) | Pharmaceutical extracts and uses thereof | |
PT2923578T (en) | Snack-product and manufacture thereof | |
GB201411148D0 (en) | New pharmaceutical uses |